Research Topics
Species | Olivier C MeyerSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritisOlivier Meyer
Rheumatology Unit, Assistance Publique Hopitaux de Paris, Bichat University Hospital, 75018 Paris, France
Arthritis Res Ther 8:R40. 2006..In conclusion, serially determined anti-CCP2 antibodies during the first three years of follow-up performs better than baseline determination for predicting radiographic progression in patients with early RA...- Prognostic markers for systemic sclerosisOlivier Meyer
Assistance Publique Hopitaux de Paris, Hopital Bichat, 46, rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 73:490-4. 2006..Other serum markers for organ involvement are under study, although their predictive performance remains to be evaluated... - Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective studyNatacha Courvoisier
Service de Rhumatologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris, 75012, France
Arthritis Res Ther 10:R106. 2008..The objectives of this study were to determine the predictive factors of long-term radiographic outcome of rheumatoid arthritis (RA) and to describe the relationship between joint damage and disability over the course of the disease... - Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapyPascale Nicaise Roland
Immunology and Haematology Department, Bichat Claude Bernard Teaching Hospital, AP HP, Paris Cedex 18, France
Arthritis Res Ther 10:R142. 2008..The aims of this study were to evaluate the usefulness of anti-MCV for diagnosing RA in anti-CCP-negative patients and to monitor anti-MCV titres during infliximab therapy for RA... - Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patientsMichel De Bandt
Centre hospitalier d Aulnay sous Bois, Service de Rhumatologie, Boulevard Ballanger, Aulnay sous Bois F 93600, France
Arthritis Res Ther 11:R157. 2009.... - Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapyOlivier Meyer
Department of Rheumatology, AP HP, Bichat Paris 7 University Hospital, CHU Bichat, 46 rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 74:73-8. 2007..The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA... - Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosusOlivier C Meyer
Rheumatology Unit, Bichat Hospital, APHP, 75018 Paris, France
Arthritis Res Ther 11:R87. 2009..Autoantibodies against C1q correlate with lupus nephritis. We compared titers of anti-C1q and anti-dsDNA in 70 systemic lupus erythematosus patients with (n = 15) or without (n = 55) subsequent biopsy-proven lupus nephritis... - Interferons and autoimmune disordersOlivier Meyer
Rheumatology Department, Bichat Teaching Hospital, 75018 Paris, France
Joint Bone Spine 76:464-73. 2009..Immunomodulation strategies designed to decrease interferon overactivity are being evaluated in patients with systemic lupus erythematosus... - Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional studyOlivier Meyer
Universite Paris 7 Denis Diderot, UFR de Medecine, APHP Hôpital Bichat, Service de Rhumatologie, Paris, France
J Rheumatol 37:125-30. 2010..To determine the prevalence of anti-RNA polymerase III autoantibodies in French patients with systemic sclerosis (SSc) and to identify the associated clinical manifestations... - Anti-CRP antibodies in systemic lupus erythematosusOlivier Meyer
Service de Rhumatologie, CHU Bichat, AP HP, 46, rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 77:384-9. 2010..CRP/anti-CRP immune complexes developed in the arterial wall may promote growth of the atheroma plaque... - Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosisOlivier C Meyer
Rheumatology Unit, Bichat Hospital, Paris, France
J Rheumatol 34:104-9. 2007..To investigate the specificities of antinuclear antibodies (ANA) associated with systemic sclerosis (SSc) disease classification and internal organ involvement among patients with SSc of different origins (European and American)... - Angiotensin-converting enzyme gene does not contribute to genetic susceptibility to systemic sclerosis in European CaucasiansJulien Wipff
Paris Descartes Université, Rhumatologie A, Hopital Cochin, AP HP, Paris, France
J Rheumatol 36:337-40. 2009..To determine whether angiotensin-converting enzyme (ACE) polymorphisms including I/D and 2 single-nucleotide polymorphisms (SNP) affect susceptibility to systemic sclerosis (SSc) in a large French Caucasian population... - Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trialMartin Soubrier
Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
Rheumatology (Oxford) 48:1429-34. 2009..To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status... - Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritisAlexandra Bruns
Rheumatology Department, Bichat Teaching Hospital, AP HP, CHU Bichat, 46 rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 76:248-53. 2009.... - Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patientsJulien Wipff
Department of Rheumatology A, Paris Descartes University, Medical Faculty, Cochin Hospital, AP HP, Paris, France
J Rheumatol 35:643-9. 2008..Significant associations have been found with the fibrillin-1 gene (FBN1) in Choctaw and Japanese populations. We investigated FBN1 polymorphisms in cohorts of European Caucasian patients... - Rituximab therapy in rheumatoid arthritis in daily practiceNoémie Assous
Department of Rheumatology A and Rheumatology B, Paris Descartes University, Medical Faculty, Cochin Hospital, AP HP, Paris, France
J Rheumatol 35:31-4. 2008..Our aim was to assess in routine care the effects of rituximab in patients with RA who had experienced an inadequate response to anti-tumor necrosis factor-alpha (TNF-alpha) agents or had a contraindication to these drugs... - Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patientsJerome Avouac
Rheumatology A Department, Paris Descartes University, Cochin Hospital, Paris, France
J Rheumatol 37:608-14. 2010..To assess the prevalence and potential associations with the systemic sclerosis (SSc) phenotype of additional autoimmune diseases (AID)... - Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferencesBruno Fautrel
Department of Rheumatology, Groupe Hospitalier Pitie Salpetriere, Paris, France
Arthritis Rheum 61:425-34. 2009..To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA)... - The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz
GenHotel EA 3886, University Evry Paris 7 Medical School, Member of the AutoCure European Consortium, Evry Genopole Cedex, France
Ann Rheum Dis 70:117-21. 2011..Interferon regulatory factors, such as IRF5, coordinate type I IFN expression. Multiple IRF5 variants were suggested as autoimmunity susceptibility factors... - Association of metalloproteinase gene polymorphisms with systemic sclerosis in the European Caucasian populationJulien Wipff
Universite Paris Descartes, AP HP, Hopital Cochin, France
J Rheumatol 37:599-602. 2010..Our aim was to determine whether polymorphisms of the MMP2, MMP9, and MMP14 genes confer susceptibility to SSc in a large population... - Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severityPhilippe Dieude
Service de Rhumatologie, Hopital Bichat Claude Bernard, APHP, Université Diderot Paris 7, Paris, France
J Rheumatol 37:987-92. 2010..Our aim was to investigate whether IRF5 haplotypes confer susceptibility to SSc, and to perform genotype haplotype-phenotype correlation analyses... - Association study of serotonin transporter gene (SLC6A4) in systemic sclerosis in European Caucasian populationsJulien Wipff
Service de Rhumatologie A, Hopital Cochin, 27 rue du Faubourg St Jacques, 75014 Paris, France
J Rheumatol 37:1164-7. 2010..Our objective was to determine whether polymorphisms of SLC6A4 confer susceptibility to SSc and its vascular phenotype... - Ankylosing spondylitis and systemic sclerosis: a rare combinationDieu Donné Ouédraogo
Service de Rhumatologie, CHU Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
Joint Bone Spine 76:290-2. 2009..This case-report confirms that two inflammatory joint diseases may co-exist, particularly in patients carrying one or two susceptibility alleles to both diseases... - Predominant cervical involvement in patients with psoriatic arthritis: report of two casesDieu Donné Ouédraogo
Rheumatology Department, Bichat Teaching Hospital, Paris Cedex 18, France
Joint Bone Spine 74:175-8. 2007..TNFalpha antagonist therapy (infliximab followed by etanercept) in one patient and phenylbutazone therapy in the other improved the symptoms and led to shrinkage of the pannus... - Evaluating inflammatory joint disease: how and when can autoantibodies help?Olivier Meyer
Rheumatology Department, Bichat Teaching Hospital, 46, rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 70:433-47. 2003..In microscopic polyangiitis the ANCAs are peripheral and correspond by ELISA to antimyeloperoxidase antibodies. Tests for other antibodies are less often needed to evaluate inflammatory joint disease... - [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives]Olivier Meyer
Service de Rhumatologie, Hopital Bichat, 46 rue Henri Huchard 75018 Paris
Bull Acad Natl Med 187:935-54; discussion 954-5. 2003..Cytokines with anti-inflammatory effect (IL4, IL10, IL13...) can also be used for treatment of RA in association with anti-TNF alpha or anti-IL1 beta... - Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patientsCéline Grosjean
Department of Rheumatology and Department of Immunology, Bichat Teaching Hospital, Paris, France
J Rheumatol 37:639-43. 2010..To determine the prevalence of the most often tested autoantibodies in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome... - Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryBenjamin Terrier
Bicetre Hospital, Assistance Publique Hopitaux de Paris, and Paris 11 University, Le Kremlin Bicetre, France
Arthritis Rheum 62:2458-66. 2010..However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off-trial patients with SLE seen in regular clinical practice... - Parvovirus B19 and autoimmune diseasesOlivier Meyer
Rheumatology Department, Hopital Bichat, 46, rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 70:6-11. 2003..Here again, the number of clinical cases is small... - NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondylarthropathyJamel El Benna
INSERM U479 and Rheumatology Department, C H U Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France
Inflammation 26:273-8. 2002..This could be the result of the presence of high levels of priming agents such as TNFalpha and IL-8 but not GM-CSF... - [CREST syndrome]Olivier Meyer
Service de Rhumatologie, Hopital Bichat, 46, rue Henri Huchard, 75877 Paris Cedex 18
Ann Med Interne (Paris) 153:183-8. 2002..Pulmonary hypertension is a very late event and the prognosis is very severe (mortality rate of 50% after 2 years)... - Hip involvement in patients with familial Mediterranean fever. A review of ten casesMohamed Younes
Rheumatology Department (Professor O. Meyer, Bichat Teaching Hospital, 46, rue Henri-Huchard, 75018 Paris, France
Joint Bone Spine 69:560-5. 2002..The association of FMF and AS (usually without the HLA-B27 antigen) has been well documented, although the pathogenic mechanisms that link these two conditions remain unknown... - [Anti-SSA/Ro and anti-SSB/La antibodies. What's new?]Olivier Meyer
Service de Rhumatologie, Hopital Bichat, 46, rue Henri Huchard, 75877 Paris Cedex 18
Ann Med Interne (Paris) 153:520-9. 2002..Other factors must be taken into account to explain discordant twins (with and without CCHB). More recently anti-Ro/SSA antibodies were associated with QT interval prolongation in newborns without CCHB... - Neonatal cutaneous lupus and congenital heart block: it's not all antibodiesOlivier Meyer
Rheumatology Department, Bichat Teaching Hospital, Denis-Diderot University, 75018, Paris, France
Lancet 362:1596-7. 2003 - [Safety and efficacy of vaccination in patients with auto-immune diseases]Olivier Meyer
Service de Rhumatologie, , 75018 Paris
Rev Prat 54:1631-4. 2004 - Rheumatoid nodulosis. Two cases with destructive polyarthritis after 20 yearsFabienne Roux
Rheumatology Department, Bichat Teaching Hospital, 46, rue Henri Huchard, 75018 Paris, France
Joint Bone Spine 73:208-11. 2006..In conclusion, these two cases establish that rheumatoid nodulosis can occur as a presentation of rheumatoid arthritis with a potential for severe joint damage after many years... - A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitidesCorneliu Henegar
Hopital Cochin, Paris 5 René Descartes University, Assistance Publique Hopitaux de Paris, France
Arthritis Rheum 58:1528-38. 2008..To establish a set of clinical and paraclinical criteria potentially useful as a diagnostic screening tool for polyarteritis nodosa (PAN)... - Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departmentsNatacha Thelier
Department of Rheumatology A, Paris Descartes University, Paris, France
J Rheumatol 35:1622-8. 2008..To analyze the pattern of osteoarticular lesions in patients with sarcoidosis hospitalized in 4 rheumatology departments... - Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patientsStefan N Hartmann
Exploratory Clinical Development, Novartis Pharma AG, Basel, Switzerland
Ann Pharmacother 38:1582-7. 2004..Methotrexate and nonsteroidal antiinflammatory drugs are frequently coadministered in the treatment of rheumatoid arthritis (RA)...